Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 16/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.38 |
| ▸ | METAP2 | P50579 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8220977 | 0.88 | CACNA1H (0.47) | CACNA1HMDM2TP53 | |
| SCHEMBL8229542 | 0.77 | CACNA1H (0.71) | CACNA1HMDM2 | |
| SCHEMBL12844637 | 0.76 | CACNA1H (0.43) | CACNA1H | |
| SCHEMBL8210807 | 0.74 | CACNA1H (0.47) | CACNA1HMDM2TP53 | |
| SCHEMBL8202485 | 0.71 | CACNA1H (0.51) | CACNA1H | |
| SCHEMBL8228606 | 0.71 | CACNA1H (0.48) | CACNA1H | |
| SCHEMBL14267020 | 0.68 | CACNA1H (0.80) | CACNA1H | |
| SCHEMBL12876090 | 0.67 | CACNA1H (0.48) | CACNA1H | |
| SCHEMBL12876244 | 0.67 | CACNA1H (1.00) | CACNA1H | |
| SCHEMBL8209942 | 0.65 | HSD11B1 (0.50) | CACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902157-B2 | Spirocyclic azetidin(one); e.g. 2,7-diazaspiro[3.5]nonan-1-one; T-type calcium channel blockers; Niemann-Pick C1-like (NPC1L1) antagonists | SCHERING CORPORATION (US) | 2011-03-08 | — | — | US | disclosed |
| US-20080070889-A1 | AZETIDINE AND AZETIDONE DERIVATIVES USEFUL IN TREATING PAIN AND DISORDERS OF LIPID METABOLISM | SCHERING CORPORATION | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070889-A1 | AZETIDINE AND AZETIDONE DERIVATIVES USEFUL IN TREATING PAIN AND DISORDERS OF LIPID METABOLISM | CYP46A1, OPRD1, OPRK1 | CACNA1H 1386/4885MDM2 2670/4885METAP2 1918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.